http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102067261-B1

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5042
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-56
filingDate 2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2020-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2020-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-102067261-B1
titleOfInvention Sustained-release pharmaceutical composition comprising mirabegron And method for manufacturing the same
abstract The present invention is a sustained-release pharmaceutical composition comprising a mira begron and a method for preparing the same Regarding, more specifically, a drug moiety comprising a mirabegron or a pharmaceutically acceptable salt thereof and a cation exchange resin; And a sustained-release pharmaceutical composition formed on the outer surface of the drug part and including a sustained-release base coating, and a sustained-release pharmaceutical composition having a sustained-release base coating layer formed on the outer surface of the Mirabegron-resin composite. According to the present invention, since the sustained-release pharmaceutical composition comprising mirabegron is a sustained-release pharmaceutical composition in the form of particulates, when applied to elderly and pediatric patients with irritable bladder syndrome, it will provide excellent drug efficacy and ease of taking. Can be.
priorityDate 2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426260389
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9865528
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557048
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559508
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5462222
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24832091
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24832095
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426260387
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419496318

Total number of triples: 26.